ATE184201T1 - Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln - Google Patents

Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln

Info

Publication number
ATE184201T1
ATE184201T1 AT93904633T AT93904633T ATE184201T1 AT E184201 T1 ATE184201 T1 AT E184201T1 AT 93904633 T AT93904633 T AT 93904633T AT 93904633 T AT93904633 T AT 93904633T AT E184201 T1 ATE184201 T1 AT E184201T1
Authority
AT
Austria
Prior art keywords
drug
attached
copolymeric
carrier
anticancer
Prior art date
Application number
AT93904633T
Other languages
English (en)
Inventor
Jindrich Kopecek
Nancy Krinick
Original Assignee
Univ Utah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah filed Critical Univ Utah
Application granted granted Critical
Publication of ATE184201T1 publication Critical patent/ATE184201T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer
    • Y10S530/816—Attached to the carrier via a bridging agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93904633T 1992-01-21 1993-01-21 Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln ATE184201T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/822,924 US5258453A (en) 1992-01-21 1992-01-21 Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light

Publications (1)

Publication Number Publication Date
ATE184201T1 true ATE184201T1 (de) 1999-09-15

Family

ID=25237341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93904633T ATE184201T1 (de) 1992-01-21 1993-01-21 Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln

Country Status (14)

Country Link
US (1) US5258453A (de)
EP (1) EP0621880B1 (de)
JP (1) JPH08500327A (de)
KR (1) KR100217186B1 (de)
AT (1) ATE184201T1 (de)
AU (1) AU663167B2 (de)
CA (1) CA2128330A1 (de)
DE (1) DE69326322T2 (de)
DK (1) DK0621880T3 (de)
FI (1) FI943430A (de)
HU (1) HUT68082A (de)
PL (1) PL172184B1 (de)
RU (1) RU94038047A (de)
WO (1) WO1993014142A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5482719A (en) * 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
US20040071637A1 (en) * 1993-04-27 2004-04-15 Elia James P. Method for repairing a damaged portion of a human organ
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5444650A (en) * 1994-01-25 1995-08-22 Nippondenso Co., Ltd. Semiconductor programmable read only memory device
US5599831A (en) * 1994-05-27 1997-02-04 Poretz; Ronald D. Method of preparation of pharmaceutical compositions
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
CN1090022C (zh) * 1995-04-04 2002-09-04 俄克拉荷马创伤治疗所 通过光动力疗法与免疫佐剂联合应用治疗癌症
US6316007B1 (en) 1995-04-04 2001-11-13 Wound Healing Of Oklahoma Combined physical and immunotherapy for cancer
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6493570B1 (en) 1998-11-02 2002-12-10 Photogen, Inc. Method for improved imaging and photodynamic therapy
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
JP2003516305A (ja) * 1997-08-05 2003-05-13 ワトソン ファーマシューティカルズ， インコーポレイテッド インターロイキン−２レセプターに標的化された結合体
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
CA2317549C (en) 1998-01-05 2006-04-11 University Of Washington Composition for enhancing transport through lipid-containing membranes, and uses thereof
US6087952A (en) * 1998-03-06 2000-07-11 Mobile Information Systems, Inc. Remote mobile data suite and method
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
US20030223978A1 (en) * 1998-05-22 2003-12-04 Nabi Ivan R. Conjugates of an AMF ligand and a cytotoxic molecule for use in cancer therapy
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
US6222093B1 (en) * 1998-12-28 2001-04-24 Rosetta Inpharmatics, Inc. Methods for determining therapeutic index from gene expression profiles
US20030114366A1 (en) * 1999-01-11 2003-06-19 Francis J. Martin Microfabricated particles and method for treating solid tumors
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
AU1820400A (en) * 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
AU2764801A (en) * 2000-01-07 2001-07-24 University Of Washington Enhanced transport of agents using membrane disruptive agents
US6455073B1 (en) 2000-07-10 2002-09-24 Enzrel, Inc. Covalent microparticle-drug conjugates for biological targeting
US6454790B1 (en) * 2000-07-21 2002-09-24 Ceramoptec Industries, Inc. Treatment for Barrett's syndrome
KR20080080685A (ko) 2000-11-29 2008-09-04 피씨아이 바이오테크 에이에스 사이토졸 내로의 분자 전달을 위한 광화학적 내부이행
WO2002049672A2 (en) * 2000-12-21 2002-06-27 Mcgill University Conjugates of antibodies and anticancer drugs
ES2300439T3 (es) * 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002090390A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates : targeted delivery of anti-cancer drugs to cancer cells
US20030124742A1 (en) * 2001-08-22 2003-07-03 Prakash Ramesh K. Conjugates targeted to target receptors
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
WO2003051113A1 (en) 2001-12-14 2003-06-26 The University Of Wyoming Methods and compositions for controlled release of drugs
US6846311B2 (en) * 2002-04-02 2005-01-25 Acueity, Inc. Method and apparatus for in VIVO treatment of mammary ducts by light induced fluorescence
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
ATE359802T1 (de) * 2002-10-04 2007-05-15 Photokinetix Inc Photokinetische abgabe von biologisch aktiven subtanzen unter verwendung von pulsierendem inkohaerentem licht.
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
ES2641570T3 (es) * 2004-03-31 2017-11-10 University Of Utah Research Foundation Sistemas de suministro macromoleculares para imagenología no invasiva, evaluación y tratamiento de artritis y otras enfermedades inflamatorias
US20070287680A1 (en) * 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
EP1888115A2 (de) * 2005-05-16 2008-02-20 Universite De Geneve Verbindungen für die fotochemotherapie
US7465312B2 (en) 2006-05-02 2008-12-16 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20070299431A1 (en) * 2006-05-02 2007-12-27 Green Medical, Inc. Systems and methods for treating superficial venous malformations like spider veins
US20090326435A1 (en) * 2006-05-02 2009-12-31 Green Medical, Inc. Systems and methods for treating superficial venous malformations like varicose or spider veins
WO2007143209A2 (en) * 2006-06-02 2007-12-13 University Of Virginia Patent Foundation Luminescent diketonate polymers
EP2492684B1 (de) 2006-06-02 2016-12-28 President and Fellows of Harvard College Neugestaltung von Proteinoberflächen
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
JP2012505228A (ja) * 2008-10-07 2012-03-01 レクサン ファーマシューティカルズ インコーポレイテッド Ｈｐｍａ−ドセタキセルまたはゲムシタビンコンジュゲートおよびその使用
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
JP2012525146A (ja) * 2009-04-28 2012-10-22 プレジデント アンド フェロウズ オブ ハーバード カレッジ 細胞透過のための過剰に荷電されたタンパク質
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
BR112012008772A2 (pt) 2009-10-13 2017-06-20 Rexahn Pharmaceuticals Inc sistemas poliméricos para a liberação de agentes anti-câncer
US8492339B2 (en) * 2009-10-26 2013-07-23 Empire Technology Development Llc Angiogenesis promoted by caged growth factors
WO2011112482A2 (en) 2010-03-08 2011-09-15 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
EP3858385A3 (de) 2010-05-25 2021-10-27 Syndevrx, Inc. Polymer-konjugierte metap2-hemmer und therapeutische verfahren zu ihrer verwendung
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US8883503B2 (en) 2011-06-23 2014-11-11 Indian Institute Of Technology Kanpur Hydrogel scaffolds for tissue engineering
DK2774625T3 (en) * 2011-09-05 2017-06-12 Hiroshi Maeda POLYMER TYPE FLUORESCING MOLECULE PROBE
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
DK2804611T3 (da) 2012-01-20 2020-11-09 Immunophotonics Inc Chitosanafledte forbindelser
US11111316B2 (en) 2012-01-20 2021-09-07 Immunophotonics, Inc. Chitosan-derived compositions
DK2984085T3 (da) 2013-04-10 2019-10-21 Syndevrx Inc Modificerede eller polymerkonjugerede fumagillol metap2-hæmmere til anvendelse i behandling af fedme
JP2019501898A (ja) 2015-12-10 2019-01-24 シンデブルックス，インコーポレイティド フマギロール誘導体およびその多形体
KR20180100663A (ko) 2016-01-11 2018-09-11 신데브알엑스, 인크. 대사 기능장애에 의하여 유도된 종양에 대한 치료
MX2018015916A (es) 2016-06-16 2019-03-28 Oncoselect Therapeutics Llc Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
JP6894747B2 (ja) * 2017-04-19 2021-06-30 キヤノン株式会社 重合体
AU2019366819A1 (en) 2018-10-26 2021-06-03 Syndevrx Inc. Biomarkers of MetAP2 inhibitors and applications thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0103184B1 (de) * 1982-08-12 1990-01-17 Kanegafuchi Chemical Industry Co., Ltd. Aktivierung bioverträglicher Terpolymere mit biologischen Stoffen, deren anzubindende Komplemente pathologische Effektoren sind
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
EP0213811A3 (de) * 1985-08-16 1987-09-09 Johnson Matthey, Inc., Bakteriozin-gerichtete Verbindungen zur Krebstherapie

Also Published As

Publication number Publication date
AU3593093A (en) 1993-08-03
FI943430A0 (fi) 1994-07-20
DE69326322T2 (de) 2000-02-17
US5258453A (en) 1993-11-02
AU663167B2 (en) 1995-09-28
FI943430A (fi) 1994-09-20
WO1993014142A1 (en) 1993-07-22
DK0621880T3 (da) 1999-12-20
EP0621880A1 (de) 1994-11-02
JPH08500327A (ja) 1996-01-16
HU9402142D0 (en) 1994-09-28
KR100217186B1 (ko) 1999-09-01
EP0621880B1 (de) 1999-09-08
HUT68082A (en) 1995-05-29
CA2128330A1 (en) 1993-07-22
DE69326322D1 (de) 1999-10-14
RU94038047A (ru) 1996-06-10
PL172184B1 (pl) 1997-08-29
EP0621880A4 (de) 1995-04-19

Similar Documents

Publication Publication Date Title
ATE184201T1 (de) Durch enzyme und licht aktivierbares arzneimittelabgabesystem zur gleichzeitigen abgabe von arzneimitteln
HUT43948A (en) Emulsion compositions for dosing ionizable hydrophobic medical substances which are little soluble in water and process for preparing the same
WO1988000837A3 (en) Advanced anticancer therapy and cytotoxic medicaments for its implementation
DE68918860T2 (de) Photoempfindliche mittel.
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
PT1028753E (pt) Libertacao de moleculas de poli(etilenoglicol)-conjugado a partir de hidrogeles degradaveis
CA2212537A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
BRPI0416028B8 (pt) composto, conjugados do composto, composição farmacêutica e usos do conjugado
ATE216402T1 (de) Opioid-konjugate mit endogenen trägerproteinen
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
ES2376739T3 (es) Administración conjunta de un polisacárido con un agente quimioterapéutico para el tratamiento del cáncer
EP0848948A4 (de) Lang wirksames mittel zur rektalen verabreichung
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
US7181271B2 (en) Synergism of photodynamic and electropermeation effect on cell vitality as a novel cytotoxic agent
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
CA2382885A1 (en) Rhodamine derivatives for photodynamic diagnosis and treatment
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
TR199801976T2 (xx) Mukozan�n viskozitesini en iyi duruma getirmek ve ba��rsak fonksiyonlar�n� uyarmak i�in ila�.
Osami et al. Local chemotherapy with slowly-releasing anticancer drug-polymers for malignant brain tumors
AU6207196A (en) Composition and method for treating prostate cancer
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
RU93029435A (ru) Способ лечения рака гепато-панкреато-дуоденальной зоны
Hoes et al. Macromolecular prodrugs of adriamycin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties